[go: up one dir, main page]

CL2017000540A1 - Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dimetilbenzofuran-3-carboxamida. - Google Patents

Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dimetilbenzofuran-3-carboxamida.

Info

Publication number
CL2017000540A1
CL2017000540A1 CL2017000540A CL2017000540A CL2017000540A1 CL 2017000540 A1 CL2017000540 A1 CL 2017000540A1 CL 2017000540 A CL2017000540 A CL 2017000540A CL 2017000540 A CL2017000540 A CL 2017000540A CL 2017000540 A1 CL2017000540 A1 CL 2017000540A1
Authority
CL
Chile
Prior art keywords
carboxamide
dimethoxyquinazolin
dimethylbenzofuran
oxy
crystalline forms
Prior art date
Application number
CL2017000540A
Other languages
English (en)
Inventor
Zhenping Wu
Wenji Li
Yuping Chu
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55458346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000540(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of CL2017000540A1 publication Critical patent/CL2017000540A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE AL CAMPO FARMACÉUTICO, PROPORCIONA NUEVAS FORMAS CRISTALINAS, SOLVATOS Y SUS FORMAS CRISTALINAS, DEL COMPUESTO 6-((6,7-DIMETOXIQUINAZOLIN-4-IL)OXI)-N,2-DIMETILBENZOFURAN-3-CARBOXAMIDA, COMPOSICIONES FARMACÉUTICAS, ASÍ COMO TAMBIÉN LOS MÉTODOS DE PREPARACIÓN DE LAS MISMAS Y SU USO.</p>
CL2017000540A 2014-09-10 2017-03-07 Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dimetilbenzofuran-3-carboxamida. CL2017000540A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410456350.9A CN105461702A (zh) 2014-09-10 2014-09-10 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型

Publications (1)

Publication Number Publication Date
CL2017000540A1 true CL2017000540A1 (es) 2017-09-15

Family

ID=55458346

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000540A CL2017000540A1 (es) 2014-09-10 2017-03-07 Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dimetilbenzofuran-3-carboxamida.

Country Status (35)

Country Link
US (4) US10519142B2 (es)
EP (1) EP3191475B1 (es)
JP (2) JP6655608B2 (es)
KR (2) KR20170042662A (es)
CN (3) CN105461702A (es)
AU (1) AU2015316010B2 (es)
BR (1) BR112017004000B1 (es)
CA (1) CA2958666C (es)
CL (1) CL2017000540A1 (es)
CY (1) CY1123892T1 (es)
DK (1) DK3191475T3 (es)
EA (1) EA034730B1 (es)
ES (1) ES2819242T3 (es)
FI (1) FIC20240047I1 (es)
FR (1) FR24C1055I1 (es)
HR (1) HRP20201501T1 (es)
HU (2) HUE050580T2 (es)
IL (1) IL250647B (es)
LT (1) LT3191475T (es)
MX (1) MX370791B (es)
MY (1) MY176618A (es)
NL (1) NL301307I2 (es)
NO (1) NO2024061I1 (es)
PE (1) PE20170661A1 (es)
PH (1) PH12017500451A1 (es)
PL (1) PL3191475T3 (es)
PT (1) PT3191475T (es)
RS (1) RS60829B1 (es)
SG (1) SG11201701544UA (es)
SI (1) SI3191475T1 (es)
SM (1) SMT202000511T1 (es)
TW (1) TWI718105B (es)
UA (1) UA120371C2 (es)
WO (1) WO2016037550A1 (es)
ZA (1) ZA201701320B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105461702A (zh) * 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
CN111164085B (zh) 2017-09-29 2023-04-04 杭州领业医药科技有限公司 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
CN116987069A (zh) * 2018-03-30 2023-11-03 杭州领业医药科技有限公司 呋喹替尼的共晶、其制备方法、组合物和用途
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
EP3951086B1 (en) 2019-03-28 2024-04-10 Sumitomo Heavy Industries, Ltd. Excavator
CN113200966B (zh) * 2021-04-06 2022-07-22 深圳大学 一种呋喹替尼衍生物、药物组合物和用途
GB202211142D0 (en) * 2022-07-29 2022-09-14 Macfarlan Smith Ltd Polymorphs, co-crystals and solvates of fruquintinib, processes for the preparation and use thereof
WO2024245409A1 (zh) * 2023-06-02 2024-12-05 成都苑东生物制药股份有限公司 一种vegfr抑制剂的水合物，其晶型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101575333B (zh) * 2008-05-09 2011-06-22 和记黄埔医药（上海）有限公司 一种喹唑啉衍生物及其医药用途
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN105461702A (zh) * 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型

Also Published As

Publication number Publication date
NO2024061I1 (no) 2024-12-17
US20240279208A1 (en) 2024-08-22
CN106604919B (zh) 2019-11-15
FIC20240047I1 (fi) 2024-12-17
AU2015316010B2 (en) 2018-06-14
HUE050580T2 (hu) 2020-12-28
UA120371C2 (uk) 2019-11-25
DK3191475T3 (da) 2020-09-28
HRP20201501T1 (hr) 2020-12-25
CN106604919A (zh) 2017-04-26
IL250647B (en) 2020-11-30
TW201609715A (zh) 2016-03-16
EP3191475B1 (en) 2020-07-29
US11958838B2 (en) 2024-04-16
ES2819242T3 (es) 2021-04-15
CN111018846A (zh) 2020-04-17
US20210276983A1 (en) 2021-09-09
US10519142B2 (en) 2019-12-31
TWI718105B (zh) 2021-02-11
SI3191475T1 (sl) 2021-02-26
HUS2400047I1 (hu) 2025-01-28
US20170283399A1 (en) 2017-10-05
NZ729884A (en) 2020-09-25
JP2017526710A (ja) 2017-09-14
RS60829B1 (sr) 2020-10-30
CA2958666C (en) 2020-10-06
JP6655608B2 (ja) 2020-02-26
MY176618A (en) 2020-08-18
BR112017004000B1 (pt) 2023-10-24
WO2016037550A1 (en) 2016-03-17
IL250647A0 (en) 2017-04-30
FR24C1055I1 (fr) 2025-02-21
SG11201701544UA (en) 2017-03-30
US11046674B2 (en) 2021-06-29
LT3191475T (lt) 2020-10-12
BR112017004000A2 (pt) 2017-12-05
PH12017500451A1 (en) 2017-07-31
CY1123892T1 (el) 2022-03-24
EA034730B1 (ru) 2020-03-13
CN105461702A (zh) 2016-04-06
US20200140420A1 (en) 2020-05-07
MX2017002913A (es) 2017-06-06
HK1231479A1 (zh) 2017-12-22
AU2015316010A1 (en) 2017-04-27
AU2015316010A8 (en) 2017-05-11
JP2019065019A (ja) 2019-04-25
PT3191475T (pt) 2020-09-04
SMT202000511T1 (it) 2020-11-10
NL301307I2 (nl) 2024-12-31
KR102221722B1 (ko) 2021-03-03
MX370791B (es) 2020-01-08
EP3191475A4 (en) 2018-10-03
EP3191475A1 (en) 2017-07-19
KR20170042662A (ko) 2017-04-19
PE20170661A1 (es) 2017-05-18
PL3191475T3 (pl) 2021-01-11
CN111018846B (zh) 2023-06-06
ZA201701320B (en) 2020-07-29
EA201790275A1 (ru) 2017-10-31
CA2958666A1 (en) 2016-03-17
KR20190018056A (ko) 2019-02-20

Similar Documents

Publication Publication Date Title
CL2017000540A1 (es) Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dimetilbenzofuran-3-carboxamida.
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CR20140460A (es) Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
MX387587B (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos.
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
MX374558B (es) Compuestos de heteroarilo y sus usos.
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
UY34540A (es) Heteroarilos y usos de los mismos
CL2017000372A1 (es) Composiciones novedosas, usos y métodos para hacerlas.
CR20170146A (es) Formas cristalinas de 5-cloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-yl)piperidin-1-il]pirimidina-2,4-diamina
UY34797A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
MX2019015744A (es) Composiciones farmaceuticas.
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
CL2016002247A1 (es) Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
MX2017002469A (es) Composiciones de matrices extracelulares.
UY35477A (es) ?4-amino-6-(4-sustituidos-fenil)-picolinatos y 6-amino-2-(4-sustituidos-fenil)-pirimidina-4-carboxilatos y su uso como herbicidas?.
CR20160133A (es) Derivados de fenilalanina sustituidos
CL2019002840A1 (es) Formas cristalinas de (s)-afoxolaner.
AR090830A1 (es) Cocristales de metalaxil y protioconazol y procedimientos para la fabricacion y el uso de los mismos
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
CU24283B1 (es) Composiciones farmacéuticas